102 related articles for article (PubMed ID: 15149511)
41. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
42. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study.
de Souza AW; da Silva MD; Machado LS; Oliveira AC; Pinheiro FA; Sato EI
Scand J Rheumatol; 2012 May; 41(3):227-30. PubMed ID: 22400913
[TBL] [Abstract][Full Text] [Related]
43. Etanercept combined with methotrexate for high-need psoriasis.
Driessen RJ; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
45. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial.
Ormerod AD; Shah SA; Copeland P; Omar G; Winfield A
Br J Dermatol; 2005 Apr; 152(4):758-64. PubMed ID: 15840110
[TBL] [Abstract][Full Text] [Related]
46. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
47. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis.
Lago E; Carneiro S; Cuzzi T; Magalhães G; Cássia F; Pessanha F; Ramos-e-Silva M
J Cutan Pathol; 2007 Jan; 34(1):15-21. PubMed ID: 17214849
[TBL] [Abstract][Full Text] [Related]
48. Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study.
Kunynetz R; Carey W; Thomas R; Toth D; Trafford T; Vender R
Eur J Dermatol; 2011; 21(1):89-94. PubMed ID: 21227890
[TBL] [Abstract][Full Text] [Related]
49. Short-term cyclosporin monotherapy for chronic severe plaque-type psoriasis.
Jan V; Vaillant L; Bressieux JM; Barthélemy H; Legoux A; Steiner HG; Reigneau O
Eur J Dermatol; 1999 Dec; 9(8):615-7. PubMed ID: 10586127
[TBL] [Abstract][Full Text] [Related]
50. The use of ciclosporin in psoriasis: a clinical review.
Ho VC
Br J Dermatol; 2004 May; 150 Suppl 67():1-10. PubMed ID: 15115440
[TBL] [Abstract][Full Text] [Related]
51. Leflunomide in dermatology.
Boyd AS
J Am Acad Dermatol; 2012 Apr; 66(4):673-9. PubMed ID: 21962758
[TBL] [Abstract][Full Text] [Related]
52. Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial.
Fallah Arani S; Neumann H; Hop WC; Thio HB
Br J Dermatol; 2011 Apr; 164(4):855-61. PubMed ID: 21175564
[TBL] [Abstract][Full Text] [Related]
53. [Use of biologicals in psoriasis].
Friedrich M; Philipp S; Sabat R; Asadullah K; Sterry W
Z Rheumatol; 2003 Oct; 62(5):439-49. PubMed ID: 14579031
[TBL] [Abstract][Full Text] [Related]
54. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.
Tam LS; Li EK; Wong CK; Lam CW; Li WC; Szeto CC
Ann Rheum Dis; 2006 Mar; 65(3):417-8. PubMed ID: 16474039
[No Abstract] [Full Text] [Related]
55. Pilot Study to Evaluate the Efficacy and Safety of Oral Tacrolimus in Adult Patients With Refractory Severe Plaque Psoriasis.
Mittal A; Dogra S; Narang T; Sharma A
J Cutan Med Surg; 2016 May; 20(3):228-32. PubMed ID: 26553734
[TBL] [Abstract][Full Text] [Related]
56. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus.
Tam LS; Li EK; Wong CK; Lam CW; Szeto CC
Lupus; 2004; 13(8):601-4. PubMed ID: 15462490
[TBL] [Abstract][Full Text] [Related]
57. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis.
Martin A; Gutierrez E; Muglia J; McDonald CJ; Guzzo C; Gottlieb A; Pappert A; Garland WT; Bagel J; Bacha P
J Am Acad Dermatol; 2001 Dec; 45(6):871-81. PubMed ID: 11712032
[TBL] [Abstract][Full Text] [Related]
58. Treatment of severe psoriasis and psoriatic arthritis with leflunomide.
Reich K; Hummel KM; Beckmann I; Mössner R; Neumann C
Br J Dermatol; 2002 Feb; 146(2):335-6. PubMed ID: 11903256
[No Abstract] [Full Text] [Related]
59. [Leflunomide--a new drug for pharmacological immunomodulation].
Wozel G; Pfeiffer C
Hautarzt; 2002 May; 53(5):309-15. PubMed ID: 12063741
[TBL] [Abstract][Full Text] [Related]
60. Palmoplantar pustulosis.
Wetter DA
CMAJ; 2013 Aug; 185(11):982. PubMed ID: 23209116
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
